| Spotlight |
 |
|
The two companies have secured $90m and $152m, respectively, to take their drugs to pivotal development.
|
| Latest news |
|
|
Infinimmune is targeting first-in-human studies with its longer-lasting monoclonal antibodies in 2027.
|
|
|
Alfasigma will operate directly in 18 European countries and extend its commercial activities to Canada and Japan.
|
|
|
Mereo BioPharma will be eligible for $40m in upfront and research and development payments, and up to $435m in milestones.
|
|
|
The CRISPR therapy, SNIPR001, was administered following a single-patient emergency investigational new drug application.
|
|
|
Seven diseases have been stripped from the recommendations, with changes to the MMR vaccine also advised.
|
|
|
|
